Lavanya Anandan, Ph.D.

Lead regional strategy to identify and advance next-generation therapeutics across the West Coast biotech ecosystem. For detailed information on our strategic therapeutic interests and partnering criteria, visit: https://www.csl.com/partnering

Advising Stanford innovators on successfully commercializing ideas, turning academic discoveries into meaningful patient impact.

Investor in the Women's Health and Active Aging Fund.

Advise on new investment opportunities and portfolio companies

Provided operational support to biotech portfolio companies and led proprietary investment theme development, industry research, sourcing, due diligence and market monitoring.

Building 0-to-1 companies from UCSF's world-class research. Partnering with faculty and staff to validate markets, build commercial strategies, and spin out investor-ready startups. Therapeutics & Diagnostics.

Investor and advisor focused on early-stage life science and biotech companies - Built a personal investment portfolio of 25 startups since 2021. - Advised 50+ startups, funders, and accelerators on due diligence, GTM strategy, strategic partnerships/ BD, pitch deck and fundraising. - Board Member/ Advisor/ Investor- Select Portfolio: Aikium, Actimo Labs, GapScore, LunarTree, Orain, Radcliffe, TripleBar, several in stealth.

Spearheaded venture building & corporate development for the Science & Technology Office. Orchestrated a $40M+ global investment portfolio focused on high-growth life sciences technology platforms & therapeutics innovation. Two core areas: 1) platforms using Data & AI to solve critical bottlenecks in biopharma drug discovery, development/clinical trials and manufacturing workflow, and 2) developing novel therapeutic asset platforms e.g, mRNAs and TPD/ PROTACs. Other focus areas: future of computing, technology convergence and sustainability. Led a global team across the US, Germany & China responsible for incubating new products & assets, creating new business verticals & driving partnerships and alliances- advancing the company's long-term growth agenda.

Pioneered and scaled a new business unit in the advanced biomanufacturing space, building the business from zero to a multi-million dollar revenue stream. Developed the complete business strategy, established key strategic partnerships, and led cross-functional teams across R&D and marketing to launch first-in-market products.

Drove significant revenue growth in emerging therapeutic areas by creating and executing global go-to-market strategies for novel modalities (e.g., Cell & Gene Therapy, mRNAs, ADCs). Translated customer and market insights into R&D and M&A roadmaps, directly influencing the development of next-generation products and acquisition targets for the business.

Executed business plans and commercial strategies to protect, expand, and grow sales territory; positioned our life science portfolio of products and services along the drug discovery, development and manufacturing value chain

Consultative selling focused on advanced genomics portfolio- forging partnerships with new and existing academic, biotech and pharma customers

Identified a novel estrogen-regulated biomarker using multi-omics approaches and elucidated signaling pathway critical for breast & uterine development & cancer progression.

Conducted IP analysis, market and industry analysis, and developed licensing strategies for biotech assets for the Office of Technology Licensing (OTL)